Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2024

This “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Understanding

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Overview

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a serine protease involved in cholesterol homeostasis. After binding to the complex low-density lipoprotein (LDL)-receptor, PCSK9 induces its intracellular degradation, thus reducing serum LDL clearance. PCSK9 is mainly secreted by the liver, but it is also expressed to a lesser extent in other organs. Apart from the well-known activity concerning hepatic LDL receptor-mediated pathway, PCSK9 has been supposed to potentially interfere with vascular inflammation in atherogenesis. Vascular smooth muscle cells have been demonstrated to produce higher amounts of PCSK9 as compared to endothelial cells especially in an inflammatory microenvironment. Low shear stress regions increase PCSK9 expression within SMCs, while higher shear stress gradually reduced PCSK9 expression.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor pipeline landscape is provided which includes the disease overview and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Emerging Drugs Chapters

This segment of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Emerging Drugs

Evolocumab: Amgen Evolocumab (Repatha) is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke. It is being investigated for the treatment of familial hypercholesterolemia in pediatricpatients.

ION449: Ionis Pharmaceuticals ION449 (formerly IONIS-AZ4-2.5-LRx), also known as AZD8233, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is integrally involved in the regulation of LDL-cholesterol. Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease. Pharmacological inhibition of PCSK9 substantially lowers LDL-C. ION449 is designed to reduce the liver production of PCSK9 and lower the plasma level of LDL-C and thus reduce the risk of cardiovascular disease.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

There are approx. 14+ key companies which are developing the therapies for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor. The companies which have their Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Amgen.

Phases

This report covers around 14+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drugs.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Report Insights

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drugs?
• How many Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ionis Pharmaceuticals
• Akeso Biopharma
• Amgen
• Novo Nordisk
• Civi BioPharma

Key Products

• ION449
• AK-102
• Evolocumab
• NNC 03850434
• CiVi 008
• oral PCSK9 inhibitor

This product will be delivered within 1-3 business days.